Breast cancer study uncovers how macrophages may contribute to a therapeutic weak spot

(Brigham and Women's Hospital) Clinical trials have investigated pairing PARP inhibitor therapy with immunotherapy. Researchers are already looking ahead for ways to get even more benefit from PARP inhibitors plus checkpoint inhibitors in breast cancer patients. Investigators found macrophage-mediated immune suppression to be the weak spot of PARP inhibition treatment. Findings are published in Nature Cancer.